NewAmsterdam Pharma Company N.V. (NAMS) Shareholders’ equity 2022–2025
NewAmsterdam Pharma Company N.V. (NAMS) shareholders’ equity at each fiscal year-end, per SEC filings.
$683.4MFY2025 · since FY2022: $430.1M → $683.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $683.4M | -9.8% |
| FY2024 | $757.5M | +162.7% |
| FY2023 | $288.4M | -32.9% |
| FY2022 | $430.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice